A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients Without Metastasis

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Prostate Cancer Patients
Interventions
DRUG

Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin

As preoperative neoadjuvant chemotherapy, drugss including Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) will be administered as a single agent performed 45 days before surgery:Cabazitaxel 25 mg/m2, Docetaxel 35 mg/m2, Mitoxantrone 4 mg/m2 or Satraplatin 80 mg/m2, through intravenous (IV) or oral (Satraplatin) administration. IV or oral administration once every 7 days, totally 4 cycles. There is a 17-day interval between the last dose and surgery.

Trial Locations (2)

200032

RECRUITING

Zhongshan Hospital, Shanghai

266035

RECRUITING

Qilu Hospital of Shandong University, Qingdao

All Listed Sponsors
collaborator

Fudan University

OTHER

collaborator

Qilu Hospital of Shandong University

OTHER

lead

Shanghai Jiao Tong University School of Medicine

OTHER